Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medistep HealthcareNSE:MEDISTEP 22 Return-on-Tangible-Asset is 18.09% as of Sep. 2025, which is 19% above its 10-year median of 15.16. GuruFocus rates NSE:MEDISTEP with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 120 Medical Distribution companies, Medistep Healthcare ranks better than 96.67% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Medistep Healthcare's annualizedNet Income for the quarter that ended in Sep. 2025 was ₹59.4 Mil. Medistep Healthcare's average total tangible assets for the quarter that ended in Sep. 2025 was ₹328.4 Mil. Therefore, Medistep Healthcare's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2025 was 18.09%.
The historical rank and industry rank for Medistep Healthcare's Return-on-Tangible-Asset or its related term are showing as below:
NSE:MEDISTEP'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 2.67 Med: 15.16 Max: 22.47
Current: 16.53
During the past 4 years, Medistep Healthcare's highest Return-on-Tangible-Asset was 22.47%. The lowest was 2.67%. And the median was 15.16%.
NSE:MEDISTEP's Return-on-Tangible-Asset is ranked better than 96.67% of 120
companies
in the Medical Distribution industry
Industry Median: 2.43
vs NSE:MEDISTEP: 16.53
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Medistep Healthcare Return-on-Tangible-Asset Related Terms
Medistep Healthcare Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Medistep Healthcare's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MEDISTEP vs MCK, COR, CAH: Return-on-Tangible-Asset Comparison
For the Medical Distribution subindustry, Medistep Healthcare's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistep Healthcare Return-on-Tangible-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medistep Healthcare's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Medistep Healthcare's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Sep. 2025) net income data.
What does a Return-on-Tangible-Asset of 18.09% mean?
Medistep Healthcare (NSE:MEDISTEP) has a Return-on-Tangible-Asset of 18.09% as of Sep. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Medistep Healthcare and its competitors. This is 19% above median its historical median of 15.16. Over the past decade, Medistep Healthcare's Return-on-Tangible-Asset has ranged from 2.67 to 22.47. According to the industry distribution chart, Medistep Healthcare ranks #4 out of 120 companies in the Medical Distribution industry, placing it in the top 3.3%.
Is Medistep Healthcare's Return-on-Tangible-Asset too high?
Medistep Healthcare's current Return-on-Tangible-Asset of 18.09% is 19% above median its 10-year median of 15.16. Over the past 10 years, this metric has ranged from a low of 2.67 to a high of 22.47. The Medical Distribution industry median Return-on-Tangible-Asset is 2.43. Medistep Healthcare's value of 18.09% is 644.4% above this industry median. Based on the distribution chart, Medistep Healthcare ranks #4 out of 120 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Medistep Healthcare has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Medistep Healthcare's Return-on-Tangible-Asset compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Medistep Healthcare ranks #4 out of 120 companies for Return-on-Tangible-Asset. This places Medistep Healthcare in the top 3% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.43. Medistep Healthcare's value of 18.09% is 644.4% above this benchmark. Historically, Medistep Healthcare's own Return-on-Tangible-Asset has ranged from 2.67 to 22.47 over the past decade. While the company's 10-year median is 15.16 vs. the industry median of 2.43, Medistep Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Distribution company?
The median Return-on-Tangible-Asset among Medical Distribution companies is 2.43, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistep Healthcare's current Return-on-Tangible-Asset of 18.09% is 644.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Medistep Healthcare and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Asset is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistep Healthcare's current Return-on-Tangible-Asset is 18.09%, which is 19% above median its own 10-year median of 15.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistep Healthcare stock overvalued right now?
Medistep Healthcare (NSE:MEDISTEP) has a current Return-on-Tangible-Asset of 18.09%. The current Return-on-Tangible-Asset is 18.09%, which is 19% above median its 10-year median of 15.16 and 644.4% above the Medical Distribution industry median of 2.43. Medistep Healthcare's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Medistep Healthcare (NSE:MEDISTEP), the current Return-on-Tangible-Asset is 18.09% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medistep Healthcare Ltd operates in the pharmaceutical and healthcare product sectors. Its business includes manufacturing intimate care and hygiene products such as sanitary pads, as well as nutraceutical products like energy powders. The company also trades a variety of pharmaceutical, surgical, and medical equipment products. Medistep Healthcare's operations focus mainly on the western region of India, particularly in Gujarat. Its Core business activity is divided into the following categories: a) Trading of Pharmaceutical & Surgical products, b) Trading & Manufacturing of Nutraceuticals and Intimate care & hygiene products. The company generates the majority of its revenue from Trading and distribution.
22GF Score
Get the complete analysis for NSE:MEDISTEP
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDISTEP has been successfully added to your 
